Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          OCE Rare Cancers ProgramOncology Center of Excellence OCE Rare Cancers Program
  
  					Promoting development of new drug and biological products to treat patients with rare cancers
	
    Share
    Post
    Linkedin

    Email
    PrintImage
              OCE Rare CancerThe mission of the Oncology Center of Excellence (OCE) Rare Cancers Program is to promote the development of safe and effective new drugs and biologics to treat patients with rare cancers. To achieve this goal, we leverage multiple OCE projects and initiatives to address the challenges of developing new treatments for cancers that affect a small number of patients. An important aspect of our work is engagement with multiple stakeholders both inside and outside of FDA to identify opportunities to decrease obstacles, better harness scientific knowledge, and strengthen coordination to facilitate efficient drug development.

Given that rare cancers comprise a multitude of cancer types affecting a heterogenous array of patient populations, OCE recognizes that a unidimensional, one-size-fits-all approach is not sufficient to achieve this mission. Instead, OCE uses the following  programs to develop a context-specific approach that is tailored to the unique patient needs and aspects of each rare cancer:

Oncology Real World Evidence Program
	OCE Scientific Collaborative
	Patient-Focused Drug Development Program
	Pediatric Oncology Program
	Project Catalyst
	Project Community
	Project Confirm
	Project Equity
	Project Facilitate
	Project Orbis
	Project Renewal
	Project Significant
	Project SocratesFrequently Asked Questions

***What is a rare cancer?***

Although there is no universally accepted definition for a rare cancer, the Orphan Drug Act defines a rare disease or condition as one which affects less than 200,000 people in the United States (U.S). The National Institute of Health defines rare cancers as those that affect fewer than 40,000 people in the U.S., and many cancer types are even rarer. Additionally, there are also rare subsets of some more common cancers, such as lung cancer or breast cancer. These subsets can be defined based upon molecular subtype (such as ROS-1 positive lung cancer) or in some cases, on unique demographic characteristics of patients affected by the cancer (such as breast cancer in men or pediatric melanoma).

***What are some of the challenges to developing drugs to treat rare cancers?***

Although the challenges to rare cancer drug development vary and may not be unique to rare cancers, they can include one or more of the following:

Difficulty enrolling sufficient number of patients to clinical trials
	Decreased financial incentives for drug development
	Insufficient understanding of the cancer pathophysiology, molecular characteristics, and natural history
	Limited or lack of timely access to molecular testing to determine eligibility for treatment with targeted therapies
	Difficulty conducting randomized trials, due to small patient numbers or lack of appropriate therapy to use as a comparator.***How does OCE work to address challenges to developing drugs to treat rare cancers?***

The OCE works in conjunction with the Office of Oncologic Diseases to proactively address the challenges that are common to rare cancer drug development as a whole and those that are specific to each rare cancer type. A few examples are provided below.

Project Community and Project Equity work together to help promote a collaborative, inclusive approach to clinical trial awareness and enrollment for a diverse patient population.
	The Pediatric Oncology Program issues Pediatric Written Requests to incentivize development of drugs for pediatric cancers and works with stakeholders in the pediatric community to facilitate drug development.
	The OCE Scientific Collaborative supports research to enhance knowledge of the pathophysiology of rare cancers and development of preclinical models of rare cancers to support drug development.
	Oncology RWE Program works with OOD review divisions to provide advice regarding use of real-world data and real-world evidence to facilitate drug development; particularly relevant when considering strategies for evidence generation in rare populations .
	Project Significant explores use of Bayesian and other statistical methodologies to demonstrate effectiveness of drugs in trials with small patient numbers.The OCE also works closely with other FDA offices such as the Office of Orphan Product Development and the Division of Rare Diseases and Medical Genetics, other international regulatory agencies, and external stakeholders to expedite drug development for rare cancers.

FDA Guidances

Rare Diseases: Common Issues in Drug Development (pdf)Rare Pediatric Disease Priority Review Vouchers (pdf)Expedited Programs for Serious Conditions - Drugs and Biologics (pdf)FDARA Implementation Guidance for Industry on Pediatric Studies of Molecularly Targeted Oncology DrugsDeveloping Targeted Therapies in Low-Frequency Molecular Subsets of a Disease
	Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products
	Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
	Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
	Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products Guidance for IndustryHelpful links

CDER's Accelerating Rare disease Cures (ARC) Program
	Rare Diseases Program
	Developing Products for Rare Diseases and Conditions
	NIH: Genetic and Rare Diseases Information CenterPrevious Events:

Public Meeting: FDA Rare Disease Day 2022 - 03/04/2022
	FDA Rare Disease Day 2021

For questions or more information contact:

OCE-RareCancerProgram@fda.hhs.gov

                                                                                  Content current as of:
      05/16/2022Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop